Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

• DOI: 10.1155/2015/285193
• Publication Date: 2015-02-23T23:10:11Z
• Authors: Ulka Vaishampayan; Archana Thakur; Ritesh Rathore; Nicola Kouttab; Lawrence G. Lum
• Keywords: Bispecific antibody

Background . New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill lines, induce a Th 1 cytokine pattern upon engagement of tumor cells, prevent the development tumors, and retard growth in immunodeficient mice. These provided strong rationale our phase I dose-escalation pilot study to test ATC Her2Bi (aATC) safety men CRPC. Methods Seven 8 CRPC were evaluable after receiving two infusions per week 4 weeks. The received 2.5, 5 or 10 × 9 aATC infusion low dose interleukin-2 granulocyte-macrophage colony stimulating factor. Results There no limiting toxicities, there was partial responder 3 7 had significant decreases their PSA levels pain scores. Immune evaluations peripheral blood mononuclear 2 before immunotherapy showed increases IFN- γ EliSpot responses serum cytokines. Conclusions results provide developing II trials determine whether effective treating